BD adds two new products into its prefilled drug delivery system profile

Offers cutting edge innovations to minimize vaccine wastage, reduce dosage errors and impact public health by enabling therapy compliance for patients


With the aim to reduce medication and dosage errors and improved patient compliance to injectable drugs, two new prefilled drug delivery devices - one for chronic diseases and another for vaccination were introduced at Technovation 2015 on 10th July by BD Medical - Pharmaceutical Systems.

BD Neopak is a single-dose, ready-to-use glass prefillable syringe system. It is an advanced version of normal prefillable syringe, particularly suitable for biotech drugs, that are more sensitive in nature and require delivery devices ensuring virtually no interaction and aggregation with the drug. BD Neopak offers additional benefits of PFS such as lesser injection time, lesser errors, reduced contamination and much better productivity to patients and clinicians.

BD Uniject SCF (Sterile, Clean and ready to Fill) is a single-use prefilled auto disable injection system that protects against inappropriate needle reuse. Being tamper proof, this system can be used even by healthcare workers, for greater coverage of outreach programs such as mass immunization. Both forms of drug delivery will assist the process of administering pharmaceutical compounds to achieve desired effect far more quickly and effectively.

"In the current environment, patients demand higher quality and more reliability in injectable drug delivery systems. Therefore there is an urgent need to be able to collaborate with industry leaders and introduce cutting edge solutions that will greatly benefit Indian patients. BD as a technology and innovation driven organization has been prudent to respond to evolving needs and provide great value to customers," said Mr Murli Sundrani, business director, BD Medical-Pharmaceutical Systems, BD India.

Injectable drug delivery market is primarily driven by rising incidences of chronic diseases such as auto immune diseases, diabetes and cancer and healthcare costs are driving the growth in drug self-administration, particularly for chronic conditions. Today, prefilled drug delivery systems are considered to be the preferred mode of administering more than 50 injectable drugs. Countries like the US, Europe and Japan, pre-dominantly use the technology, while its usage is expanding in developing countries as well like in India and China.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email